Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Share-based Compensation (2016 - 2025)

Anaptysbio (ANAB) has disclosed Share-based Compensation for 10 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 3.93% year-over-year to $8.5 million, compared with a TTM value of $36.1 million through Dec 2025, up 5.94%, and an annual FY2025 reading of $36.1 million, up 5.94% over the prior year.
  • Share-based Compensation was $8.5 million for Q4 2025 at Anaptysbio, down from $9.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $10.1 million in Q1 2024 and bottomed at $3.3 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $7.3 million, with a median of $8.0 million recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 133.54% in 2022, then dropped 10.48% in 2024.
  • Year by year, Share-based Compensation stood at $4.0 million in 2021, then skyrocketed by 68.05% to $6.7 million in 2022, then grew by 21.33% to $8.1 million in 2023, then rose by 0.9% to $8.2 million in 2024, then grew by 3.93% to $8.5 million in 2025.
  • Business Quant data shows Share-based Compensation for ANAB at $8.5 million in Q4 2025, $9.2 million in Q3 2025, and $9.2 million in Q2 2025.